Venus Remedies is currently trading at Rs. 311.50, up by 0.75 points or 0.24% from its previous closing of Rs. 310.75 on the BSE.
The scrip opened at Rs. 311.55 and has touched a high and low of Rs. 315.20 and Rs. 309.05 respectively. So far 4581 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 260.00 on 06-Nov-2023.
Last one week high and low of the scrip stood at Rs. 331.00 and Rs. 303.50 respectively. The current market cap of the company is Rs. 414.51 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.18% and 57.06% respectively.
Venus Remedies has received Good Manufacturing Practices (GMP) approval with Pharmaceutical Inspection Co-operation Scheme (PIC/S) accreditation from the National Pharmaceutical Regulatory Ageney (NPRA) of Malaysia for its state-of-the-art robotic pre-filled syringe (PFS) facility at its Baddi unit.
This marks the first PIC/S GMP accreditation for Venus Remedies' PFS facility, adding to the GMPs already secured by the company from more than 25 regulatory authorities, including the WHO, European Union and Saudi Arabia. The company has more than 35 marketing authorizations for its flagship PFS drug, enoxaparin, from various important markets like Saudi Arabia, Azerbaijan, Philippines, Myanmar, Kenya, Moldova, and Nepal.
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities as it will enable Venus Remedies to seek quicker approvals from other PIC/S member countries owing to mutual recognition of this coveted certification among member states. This achievement will not only pave the way for the company's rapid expansion in new markets, but also enhance its ability to cater to the growing global demand for enoxaparin.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1778.00 |
| Dr. Reddys Lab | 1211.60 |
| Cipla | 1487.45 |
| Lupin | 2059.90 |
| Zydus Lifesciences | 946.60 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
